QCG
ELVN icon

Quadrant Capital Group’s Enliven Therapeutics ELVN Stock Holding History

Quadrant Capital Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-295
Closed -$4.54K – 2744
2025
Q4 		$4.54K Hold
295
– – ﹤0.01% 2399
2025
Q3 		$6.04K Buy
+295
New +$5.95K ﹤0.01% 2286

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Quadrant Capital Group's ELVN Position: Q1 2026 in Review

Quadrant Capital Group sold out of Enliven Therapeutics (ELVN) in Q1 2026, closing a stake of 295 shares — an estimated $4.54K sold.

Quadrant Capital Group first reported a position in ELVN in Q3 2025 and held it in 2 quarters. The position peaked at $6.04K in Q3 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Quadrant Capital Group reported no remaining Enliven Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 295 Enliven Therapeutics shares in Q1 2026, an estimated $4.54K.
  • Quadrant Capital Group first reported a position in Enliven Therapeutics in Q3 2025 and held it in 2 quarters.
  • Quadrant Capital Group's Enliven Therapeutics position peaked at $6.04K in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.